Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 184

1.

How expensive is antipsychotic polypharmacy? Experience from five US state Medicaid programs.

Valuck RJ, Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R; Medicaid Pharmacotherapy Research Consortium..

Curr Med Res Opin. 2007 Oct;23(10):2567-76.

PMID:
17848204
2.

Prevalence, utilization patterns, and predictors of antipsychotic polypharmacy: experience in a multistate Medicaid population, 1998-2003.

Morrato EH, Dodd S, Oderda G, Haxby DG, Allen R, Valuck RJ.

Clin Ther. 2007 Jan;29(1):183-95.

PMID:
17379060
3.

Healthcare costs of atypical antipsychotic use for patients with bipolar disorder in a Medicaid programme.

Qiu Y, Fu AZ, Liu GG, Christensen DB.

Appl Health Econ Health Policy. 2010;8(3):167-77. doi: 10.2165/11318830-000000000-00000.

PMID:
20408601
4.
5.

Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.

Ganguly R, Kotzan JA, Miller LS, Kennedy K, Martin BC.

J Clin Psychiatry. 2004 Oct;65(10):1377-88.

PMID:
15491242
6.

The effect of adjunctive mood stabilizers on antipsychotic utilization pattern and health resource utilization for Medicaid enrollees with schizophrenia.

Chen H, Kennedy WK, Dorfman JH, Fincham JE, Reeves J, Martin BC.

Curr Med Res Opin. 2007 Jun;23(6):1351-65. Epub 2007 May 1.

PMID:
17559734
7.

Comparison of second-generation antipsychotic treatment on psychiatric hospitalization in Medicaid beneficiaries with bipolar disorder.

Jing Y, Johnston SS, Fowler R, Bates JA, Forbes RA, Hebden T.

J Med Econ. 2011;14(6):777-86. doi: 10.3111/13696998.2011.625066. Epub 2011 Sep 29.

PMID:
21954966
8.

Psychotropic medication changes, polypharmacy, and the risk of early readmission in suicidal adolescent inpatients.

Fontanella CA, Bridge JA, Campo JV.

Ann Pharmacother. 2009 Dec;43(12):1939-47. doi: 10.1345/aph.1M326. Epub 2009 Nov 24.

PMID:
19934394
9.

Retrospective assessment of Medicaid step-therapy prior authorization policy for atypical antipsychotic medications.

Farley JF, Cline RR, Schommer JC, Hadsall RS, Nyman JA.

Clin Ther. 2008 Aug;30(8):1524-39; discussion 1506-7. doi: 10.1016/j.clinthera.2008.08.009.

PMID:
18803994
11.

Outpatient antipsychotic treatment and inpatient costs of schizophrenia.

Marcus SC, Olfson M.

Schizophr Bull. 2008 Jan;34(1):173-80. Epub 2007 Jun 19.

13.
14.
15.

Use patterns for antipsychotic medications in medicaid patients with schizophrenia.

McCombs JS, Nichol MB, Stimmel GL, Shi J, Smith RR.

J Clin Psychiatry. 1999;60 Suppl 19:5-11; discussion 12-3.

17.

Association of antipsychotic polypharmacy with health service cost: a register-based cost analysis.

Baandrup L, Sørensen J, Lublin H, Nordentoft M, Glenthoj B.

Eur J Health Econ. 2012 Jun;13(3):355-63. doi: 10.1007/s10198-011-0308-0. Epub 2011 Mar 31.

PMID:
21452062
18.

Assessing the costs of chronic obstructive pulmonary disease: the state medicaid perspective.

Marton JP, Boulanger L, Friedman M, Dixon D, Wilson J, Menzin J.

Respir Med. 2006 Jun;100(6):996-1005. Epub 2005 Nov 8.

19.

Changes in antipsychotic medication use after implementation of a Medicaid mental health carve-out in the US.

Robst J.

Pharmacoeconomics. 2012 May;30(5):387-96. doi: 10.2165/11539830-000000000-00000.

PMID:
22316397
20.

Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study.

Baandrup L, Gasse C, Jensen VD, Glenthoj BY, Nordentoft M, Lublin H, Fink-Jensen A, Lindhardt A, Mortensen PB.

J Clin Psychiatry. 2010 Feb;71(2):103-8. doi: 10.4088/JCP.08m04818yel. Epub 2009 Nov 3.

Supplemental Content

Support Center